Zomig

AstraZeneca reported that its cholesterol-lowering drug Crestor captured a 1 percent share of new prescriptions in the U.S. statin market in its first full week of launch, with a total prescription volume of 18,000. Current data show the drug now has a more than 2 percent market share of new prescriptions, with 25,000 total prescriptions. The company reported that pharmacies were stocked fully with Crestor eight days after its launch in mid-September, and samples of the drug reached nearly two-thirds of its targeted physician audience within two weeks of FDA approval.

AstraZeneca also announced FDA approval of Zomig (zolmitriptan) Nasal Spray for the acute treatment of migraine with or without aura in adults. Studies showed the 5 mg dose was effective for up to 4 hours and had a sustained headache response for up to 24 hours. The new nasal spray is positioned as an alternative for patients who experience nausea or vomiting with their migraines.

COPYRIGHT 2003 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2003 Gale Group